Biogen earnings lack blockbuster acquisition pop, but executives pledge to keep looking

first_img Senior Writer, Biotech Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He’s also a co-host of “The Readout LOUD” podcast. By Adam Feuerstein Jan. 25, 2018 Reprints What’s included? Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Biotech Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. @adamfeuerstein Biogen (BIIB) bought an early-stage ALS drug Thursday, so cue up the “sad trombones” if you were hoping for a blockbuster biotech acquisition.But Spinraza sales rebounded nicely in the fourth quarter and the multiple sclerosis business remains in good shape. Biogen offered 2018 financial guidance a tick higher than consensus. Biogen earnings lack blockbuster acquisition pop, but executives pledge to keep looking center_img Log In | Learn More GET STARTED Tags biotechfinanceSTAT+ About the Author Reprints Biogen CEO Michel Vounatsos Biogen Adam Feuerstein [email protected] What is it?last_img read more